hu14.18K322A

BIOLOGICAL3 trials

Sponsors

St. Jude Children's Research Hospital

Conditions

High-risk TumorLymphomaNeuroblastomaNeuroblastoma Recurrent

Phase 1

A Pilot Study of Immunotherapy Including Haploidentical NK Cell Infusion Following CD133+ Positively-Selected Autologous Hematopoietic Stem Cells in Children With High Risk Solid Tumors or Lymphomas

CompletedNCT02130869

St. Jude Children's Research HospitalHigh-risk Tumor, Lymphoma, Neuroblastoma

Start: 2014-10-10End: 2017-12-20Updated: 2017-12-22

Phase 2

Therapy for Children With Advanced Stage Neuroblastoma

Active, not recruitingNCT01857934

St. Jude Children's Research HospitalNeuroblastoma

Start: 2013-07-05End: 2025-12-31Updated: 2025-11-17

A Phase II Study With a Safety Run-In of the Addition of N-803 to a Chemoimmunotherapy Backbone for the Treatment of Patients With Relapsed or Refractory Neuroblastoma

RecruitingNCT07085338

St. Jude Children's Research HospitalNeuroblastoma Recurrent

Start: 2025-11-10End: 2029-02-01Target: 54Updated: 2026-02-17

Related Papers

Longitudinal NK cell kinetics and cytotoxicity in children with neuroblastoma enrolled in a clinical phase II trial

Journal for ImmunoTherapy of Cancer2020-03-0125 citations

Pre-existing antitherapeutic antibodies against the Fc region of the hu14.18K322A mAb are associated with outcome in patients with relapsed neuroblastoma

Journal for ImmunoTherapy of Cancer2020-03-015 citations

Early response rates and Curie scores at end of induction: An update from a phase II study of an anti-GD2 monoclonal antibody (mAb) with chemotherapy (CT) in newly diagnosed patients (pts) with high-risk (HR) neuroblastoma (NB).

Journal of Clinical Oncology2017-05-2013 citations

Improved clinical responses with the concomitant use of an anti-GD2 monoclonal antibody and chemotherapy in newly diagnosed children with high-risk (HR) neuroblastoma (NB): Preliminary results of a phase II study.

Journal of Clinical Oncology2016-05-2014 citations